PI3K inhibition may render BRCA-proficient breast tumor cells more responsive to PARP inhibition through ERK signaling-mediated downregulation of BRCA1/2 expression (Ibrahim et al., 2012). This evidence concerns the gene BRCA1 and breast neoplasm.